To quantify the financial impact of complications after radical cystectomy (RC) and their associations with respective 90-day costs, as RC is a morbid surgery plagued by complications and the expenditure attributed to specific complications after RC is not well characterised.
Introduction
Cancer care entails a substantial economic and societal burden [1, 2] . An increase in the overall cost of cancer care is anticipated due to a growing proportion of elderly individuals, improvements in treatment that extend survival, and integration of novel technologies [3] . Amongst cancer surgeries, radical cystectomy (RC) is one of the most clinically morbid and financially burdensome [4] . With estimated costs of up to $200 000 per patient, bladder cancer is one of the most expensive cancers to treat and also entails psychological burdens and decreased quality of life [4, 5] .
Complication rates range between 50% and 60% [6, 7] within 90 days and readmission rates vary from 20% to 30% within 30 days, both of which are amongst the highest amongst major cancer surgeries [6] [7] [8] . In fact, when examining 90-day readmission rates in RC, values may even exceed 40% [8] . Moreover, readmissions after RC may be underreported due to limitations in claims data, suggesting an even greater magnitude of this burden to the healthcare system [9] .
Despite multiple efforts to improve quality of care in RC multiple challenges remain [10] . Detailed exploration of the cost of different complications after RC may be one method to identify sources of excess healthcare expenditures. Complications lead to readmissions, and readmitted patients have higher costs of care and a worse prognosis after RC [8] .
Complications may also result in a reduction in hospital profit margin [11] . Stratification of complications by cost informs drivers of expense and highlights candidates for quality improvement initiatives. In the present study, we investigated costs of specific complications, and secondarily evaluated clinical outcomes linked to those complications.
Patients and Methods

Data Source
The Premier Hospital Database (Premier Inc., Charlotte, NC, USA) is an all-payer hospital discharge database that was developed to benchmark quality and utilisation of healthcare in the USA [12] . Longitudinal analysis is possible through a unique patient identifier. We received Institutional Review Board exemption for this study.
Study Cohort and Covariates
We used International Classification of Diseases, ninth revision (ICD-9) codes to identify adults (aged ≥18 years) who underwent RC (ICD-9 57.71, 57.79) for bladder cancer (ICD-9 188.0) between 2003 and 2013. We limited the dataset to those who underwent an elective RC (defined by Premier as RC on admission day 1 or 2 
Outcomes
We used ICD-9 codes to identify 90-day complications (Table S1 ) from the inpatient stay, readmission or emergency room visits as defined by Health Care Cost and Utilization Project (HCUP) Clinical Classification Software (CCS). Complications were categorised using CCS Level II or III designations for the specific complications of sepsis, wound dehiscence, pressure ulcer, retained foreign body, surgical laceration, perioperative haemorrhage, acute kidney injury requiring dialysis, venous thromboembolism (VTE), and central venous catheter-related blood stream infections; ICD-9 codes were based on Agency for Healthcare Research and Quality (AHRQ) Patient Safety Indicators (PSI). Complications were stratified by events that occurred during the admission for the RC (index complication) and those that occurred after discharge resulting in an emergency room visit or readmission. The complications were placed in the following categories: infectious, pulmonary, cardiac, surgical, VTE, neurological, bleeding, wound and soft tissue, genitourinary, gastrointestinal, and renal.
The Premier Hospital Database provides direct hospitalisation costs. These are distinct from hospital charges and do not need to be converted from hospital charges. These direct hospital costs were further subdivided into categories (e.g. room and board, radiology, operative room costs) to compare resource utilisation amongst the different complications. To facilitate comparison, all costs were adjusted to 2013 American dollars using the medical component of the Consumer Price Index. We also assessed length of stay (LOS), in-hospital mortality, and discharge disposition (e.g. home, home with healthcare, skilled nursing facility, and other [such as hospice, psychiatric facility, or unknown]).
Statistical Analyses
We summarised patient, hospital, and surgical characteristics with descriptive statistics. Categorical variables were compared using the chi-squared test and continuous data with Student's t-tests. The mean cost was evaluated using a generalised linear model conforming to a gamma distribution (and a log link) due to the skewed distribution of costs, and an adjusted mean cost for complications was predicted using marginal effects. LOS was evaluated with a negative binomial regression model. Surgical volume was categorised based on percentiles and determined on a year-by-year basis for both open and robotic cases [13, 14] . All outcome models were adjusted for patient characteristics (age, gender, race, marital status, insurance status, CCI score), hospital characteristics (teaching status, hospital size, location, region), and surgical characteristics (type of diversion, pelvic lymphadenectomy, operative time, transfusion, and open vs minimally invasive surgery).
Nationally representative estimates were obtained by using projection weights linked to the Premier Database that are derived from the 1998 American Hospital Association Annual Survey and validated by the 1998 National Hospital Discharge Survey. Survey weighting and hospital clustering was used for all analyses. Tests were two-sided, and a P < 0.05 was considered statistically significant. Data extraction from the Premier Database was performed using the Statistical Analysis System (SAS â , version 9.3; SAS Institute, Cary, NC, USA) and statistical analysis was performed using Stata version 14.2 (StataCorp, College Station, TX, USA).
Results
The final study cohort comprised 9 137 patients from 360 hospitals representing a weighted cohort of 57 554 patients who underwent RC for bladder cancer ( Table 1 ). The readmission rate was 19.9%. There was no difference in baseline characteristics of readmitted patients' vs nonreadmitted patients in terms of age, gender, race, obesity, marital status, payer, hospital size, teaching status, diversion type, and robotic approach. Readmitted patients tended to have a higher CCI score (P < 0.001), and had a longer operative time (P < 0.001). High-volume surgeons and hospital tended to have a lower percentage of readmitted patients (P = 0.001 and P = 0.002, respectively).
The overall 90-day complication rate was 68.3%, with a 61.8% complication rate during the index hospitalisation ( Table 2 ). The most common complication category during the index hospitalisation was gastrointestinal (35.7%) followed by bleeding complications (16.8%) and renal dysfunction (16.0%). An infectious complication was the most common complication during a readmission (13.8%), followed by renal dysfunction (10.3%), and gastrointestinal complications (9.0%). The median (interquartile range [IQR]) number of complications during an index admission was 1 (0-2) (Fig. 1A) . Of the patients who had a complication during the index admission, they tended to have multiple complications (median of 2, IQR 1-3). Patients readmitted had a median (IQR) of 3 (2-4) complications (Fig. 1B) .
Using an adjusted model, patients who did not have an index complication had a predicted LOS of 8.3 days (95% CI 8.1-8.6); patients with an index complication had an increase in their predicted LOS to 12.4 days (95% CI 12.0-12.7; P < 0.001). Compared with patients without an index complication, the greatest increase in predicted LOS was seen after VTE (3.4 days, 95% CI 2.6-4.2; P < 0.001), wound and soft tissue complications (3.4 days, 95% CI 2.7-4.2; P < 0.001), and infectious events (3.2 days, 95% CI 2.7-3.6; P < 0.001; Table S2 ). Every index complication significantly increased the LOS except for surgical complications (P = 0.055).
Patients without a perioperative complication had a predicted 90-day mean cost of $24 911 (95% CI $23 869-25 952; Fig. 2 ). The predicted 90-day cost of patients who had a complication during only the index admission was significantly higher at $34 119 (95% CI $32 691-35 546; P < 0.001; Table S3 ). Patients readmitted who did not have an index complication incurred a predicted 90-day cost of $45 487 (95% CI $42 057-48 917; P < 0.001). Patients who had both an index and readmission complication had the highest predicted cost at $54 934 (95% CI $51 649-58 219; P < 0.001).
Additionally, increased 90-day costs were associated with higher CCI score (P < 0.001), teaching hospital status (P = 0.03), longer operative times >6 h (for 6-8 h and ≥8 h [both P < 0.001], vs 4-6 h), and ≥3 units of blood transfused (3-4 units [P = 0.007], ≥4 units [P < 0.001] vs no transfusion). Decreased 90-day costs were associated with high-volume Financial impact of complications after radical cystectomy surgeons (≥90th percentile vs <70th percentile, P = 0.03), and operative times <4 h (P < 0.001).
Aside from 90-day costs, a complication during the index admission also increased the cost of that index admission by over $9 262 ($34 149.65 [95% CI $32 808-35 491] vs $24 887 [95% CI $23 869-25 904]; P < 0.001). All index complication categories significantly increased costs over those who did not have a complication (Fig. 3A) . The complication associated with the highest increase in cost during the index admission was VTE ($8 172 [95% CI $5 693-10 651]; P < 0.001) followed by infectious ($7 175 [95% CI $5 944-8 407]; P < 0.001) and wound and soft tissue complications ($6 510.74 [95% CI $4 405-8 616]; P < 0.001). The predicted mean cost of readmission due to a complication was $20 697 (95% CI 18 735-22 660). For any readmission, we presumed a baseline readmission cost of $5 599.47. Beyond this fixed cost, the complications associated with the highest additional costs were pulmonary complications ($9 429 [95% CI $7 519-11 339]; P < 0.001) followed by VTE ($8 837 [95% CI $7 226-10 448]; P < 0.001), and complications related to bleeding ($9 190 [95% CI $8 049-10 330]; P < 0.001) (Fig. 3B) .
Discussion
In the present contemporary study, we show that specific categories of complications after RC can be stratified by costs in the index stay and any subsequent readmission. We identified an overall 90-day complication rate of 68.3%, which is consistent with previous reports [6, 8, 15] . A complication leading to readmission exceeded the cost of an index complication, and having both was costlier than either category alone (Fig. 2) . We also found that the increased cost of a complication may be as high as $9 200 during the index admission and >$20 000 during readmission. Readmission complications increased hospital costs more than index complications across all categories. Beyond increased costs, a complication also increased the index LOS by 4 days (from 8 to 12 days). We found the top four costliest complications after RC during the index stay included VTE, infections, wound and soft tissue complications, and pulmonary complications (Fig. 3A) . In comparison, the top four most costly complications on readmission included pulmonary, bleeding, VTE, and gastrointestinal. Interestingly, pulmonary and VTE complications were amongst the costliest complications during both index stay and readmission. The most common 90-day complications (Table 2) included gastrointestinal (40.7%), infectious (25%), and renal (23.7%) categories. Balancing consideration for the cost and commonality of complications may inform which categories should be tackled in quality improvement efforts. Encouraging a more effective allotment of hospital resources during care for RC is essential [16] . In the present study, we identify sources of more costly complications that can inform postoperative care pathways. Whilst VTE is a major source of morbidity and mortality, it is also costly and may support use of chemoprophylaxis measures after surgery. The use of Enhanced Recovery After Surgery (ERAS) is common in RC and has been shown to reduce complications and LOS through the use of integrated multidisciplinary care [17, 18] . Early feeding, minimisation of narcotics, judicious hydration, and use of alvimopan represent several aspects of ERAS [17] . Also, hospitals have invested in decreasing complications and subsequent readmissions by arranging for early follow-up, performing follow-up telephone calls, completing medication reconciliation, and working with local hospitals [19] . Amongst certain complications that result in readmission, such as dehydration, earlier postoperative care such as an encouraging generous hydration may be beneficial to mitigate the severity of the complication [19] . Future efforts can include refinement of protocols to utilise the preoperative window, providing better communication with patients regarding expectations, and increasing hospital efficiency via consistent clinical care plans.
Most patients presenting for readmission had multiple complications. Identification and prevention of common complications is a healthcare priority and a financial goal for healthcare providers and policy makers [20, 21] . We found that VTE was one of the costliest complications after RC during the index stay and readmission, and it was found to occur in 4.1% of patients. RC patients harbour multiple risk factors for VTE including age, smoking, cardiopulmonary comorbidity, pelvic surgery, lymphadenectomy, chemotherapy, immobility, and venous catheters [22] . Moreover, VTE may raise initial costs by >$9 000 and readmission costs by >$20 000. VTE complications commonly increase hospitalisation duration, costs, and mortality [23] . Up to 33% of VTE events are diagnosed after the time of surgery [24] and specifically in RC, as many as 55% of VTE occur after discharge [25] . As increased incentives are given to lower hospital LOS, early discharge may result in a larger portion of RC patients developing VTE outside of direct medical supervision. Extended duration VTE prophylaxis, encouraging regular ambulation, compression stockings, and improved patient education may help reduce this costly complication.
Wound and infectious complications were amongst the costliest during the index stay and are relatively common at 11.2%. RC patients have predisposing factors for infectious complications including smoking history, history of chemotherapy, and poor nutrition [6, 26] prior to surgery, improving nutrition [27] , encouraging smoking cessation [28] , and promoting exercise [29] may be valuable opportunities to promote recovery and decrease complications. In addition, infectious complications may also relate to the overuse of antimicrobial prophylaxis in urological surgery, variability in practice patterns among providers, and suboptimal compliance with clinical guidelines [30] . In one study, 579 unique combinations of antimicrobial prophylaxis in RC were noted and as few as 15% received regimens based on guidelines [31] . Improved antimicrobial stewardship in urological oncology and mindful use of antimicrobials in RC can also help mitigate infectious complications or decrease related adverse outcomes including Clostridium difficile colitis [32] .
We inspected the basis of costs behind each complication. For VTE, one of the costliest complications, costs were driven by room and board, pharmacy, laboratory, and radiology costs. A review of the literature inspecting the economic burden of certain complications, such as VTE, has corroborated these categories as being the principal sources of costs [33] . Room and board are inherent to any readmission and partially explain why complications were more expensive upon readmission. For many academic hospital centres, readmissions consume a precious resource such as available beds. Also, laboratory use may represent a target initiative for lowering costs, as over utilisation or redundant laboratory studies in patients being readmitted can be identified and reduced. Obtaining more granular data about the sources of costs for specific complications may help understand resource utilisation in other healthcare settings outside of the USA.
We also found that high-volume surgeons were associated with lower costs. Regionalisation of RC to high-volume hospitals and surgeons has been shown to result in improved outcomes, with high-volume RC hospitals having lower charges, shorter stays, and lower mortality [10, 34] . A recent comparison of 90-day RC readmissions to index vs non-index hospitals (that did not perform the original surgery) showed similar hospital costs and inpatient mortality, which suggests ongoing regionalisation of care and that patients being readmitted may prefer to stay locally rather than travel long distances [35] . Developing quality improvement efforts in RC will probably originate in these high-volume centres, where implementation of ideas can be tested for clinical and economic value. Also, the heterogeneity in readmission rates and the fact that readmission complications are more expensive than index complications may catalyse efforts to disseminate successful approaches potentially by using Statewide quality improvement collaborative programmes [36] .
Identification and prevention of common complications is a healthcare priority and a financial goal for healthcare providers and policy makers [20, 21, 37] . Preventable readmissions during the first 6 months of any discharge have been estimated to account for $730 million in expenditures in the USA [38] . However, prevention of 10% of total readmissions has been estimated to potentially save~$1 billion in expenses [21] . Reducing readmissions in major surgeries, such as RC, is particularly relevant with the goal of the Hospital Readmissions Reduction Program, which promotes development and execution of processes that aim to decrease overall readmission rates [21] . In the first year alone, >2 200 hospitals received $280 million in penalties [21] and most of those were large hospitals, teaching hospitals, and safety net hospitals [20] . In addition to the financial burden imposed by readmissions, they are also discouraging to families, detrimental to the quality of life of patients, and frustrating for physicians. As healthcare legislation and financial incentives continue to emphasise the significance of readmissions to patients and hospitals, physicians involved in major operations, such as RC, may play a central role in examining and prioritising specific complications to tackle.
Limitations
The present study is subject to several limitations. First, the Premier Database lacks cancer-specific pathological data. Second, Premier captures 20% of discharges in the USA and may lack generalisability such that different healthcare settings may have discrepancies in cost data due to different insurance systems and clinical standards of care. Third, coding inaccuracies are possible, as with any retrospective approach. Fourth, we do not capture any complications managed as an outpatient. Fifth, categorisation of complications varies across studies although we used standardised reporting methodology to more precisely report outcomes [15] . Sixth, RC literature is confounded by variability in which factors are truly modifiable and also some complications are inevitable and represent high-quality care. Seventh, we do not capture the impact of each complication on patient-reported outcomes. Lastly, we use ICD-9 codes despite more updated ICD-10 codes being available.
Conclusions
Despite these limitations, we show that costs of complications after RC can be stratified, and that complications are costlier when they present as a readmission rather than as occurrences during the index stay. Complications after surgery can be examined in detail and this approach can be applied to other major oncological operations. The costs, commonality, and clinical impact of complications may guide how patients, physicians and administrators decipher which are the most important to tackle. Whilst obstacles after RC are inevitable, this surgery merits continued effort to focus on improving the quality of care we provide for patients undergoing this major operation.
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